Sugi Predict

Sugi Predict / Compounds / SCHEMBL248385

SCHEMBL248385

SCHEMBL248385

O=C(O)C1CC1c1ccc(F)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 4/20 0.50
▸ SLC9A1 P19634 1/20 0.48
▸ HTR2A P28223 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ KDM1A O60341 2/20 0.47
▸ CYP4F2 P78329 3/20 0.44
▸ CYP4A11 Q02928 3/20 0.44
▸ GPR88 Q9GZN0 1/20 0.43
▸ FFAR4 Q5NUL3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7655989 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL12915852 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL18272394 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL248384 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL15196464 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL18272446 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL29488083 1.00 FFAR1 (0.50) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL15189650 0.98 FFAR1 (0.49) FFAR1SLC9A1HTR2AHTR2CHTR2B
SCHEMBL814567 0.86 SLC9A1 (0.48) SLC9A1HTR2AHTR2CHTR2BKDM1A
SCHEMBL247915 0.86 SLC9A1 (0.48) SLC9A1HTR2AHTR2CHTR2BKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110437092-B Preparation method of ticagrelor key intermediate aromatic cyclopropane amide 泓博智源(开原)药业有限公司 2022-06-10 — — CN claimed
WO-2013144295-A1 SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS SANDOZ AG (CH) 2013-10-03 — — WO claimed
US-20230382886-A1 CONJUGATED TLR7 AND NOD2 AGONISTS UNIVERZA V LJUBLJANI (SI) 2023-11-30 — — US disclosed
CN-116600830-A Conjugated TLR7 and NOD2 agonists 卢布尔雅那大学 2023-08-15 — — CN disclosed
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2022-11-17 — — US disclosed
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS NIPPON CHEMIPHAR CO., LTD. (JP) 2022-07-21 — — US disclosed
CN-110437092-B Preparation method of ticagrelor key intermediate aromatic cyclopropane amide 泓博智源(开原)药业有限公司 2022-06-10 — — CN disclosed
EP-3950059-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS Nippon Chemiphar Co., Ltd. (JP) 2022-02-09 — — EP disclosed
EP-3825303-A1 T-TYPE CALCIUM CHANNEL BLOCKER Nippon Chemiphar Co., Ltd. (JP) 2021-05-26 — — EP disclosed
WO-2020203610-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS 日本ケミファ株式会社 2020-10-08 — — WO disclosed
WO-2020203609-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS 日本ケミファ株式会社 2020-10-08 — — WO disclosed
US-20110137056-A1 Chemical Process For Preparation Of Intermediates ASTRAZENECA AB (SE) 2011-06-09 — — US disclosed
US-20100331575-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2010-12-30 — — US disclosed
US-20100331575-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2010-12-30 — — US disclosed
US-7790927-B2 Using hypochlorite in water in presence of alkali metal hydroxide ASTRAZENECA AB (SE) 2010-09-07 — — US disclosed
US-7790927-B2 Using hypochlorite in water in presence of alkali metal hydroxide ASTRAZENECA AB (SE) 2010-09-07 — — US disclosed
EP-2049462-A1 CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES Astra Zeneca AB (SE) 2009-04-22 — — EP disclosed
US-20080071114-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2008-03-20 — — US disclosed
US-20080071114-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2008-03-20 — — US disclosed
WO-2008018822-A1 CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES ASTRAZENECA AB (SE) 2008-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071114-A1 Processes For The Preparation Of Optically Active Intermediates DHPS, CYP1B1, CYP2S1 FFAR1 1004/4885SLC9A1 4551/4885HTR2A 302/4885
US-20230382886-A1 CONJUGATED TLR7 AND NOD2 AGONISTS NOD2, TLR7, TLR9 FFAR1 228/4885SLC9A1 3717/4885HTR2A 2028/4885
US-20100331575-A1 Processes For The Preparation Of Optically Active Intermediates DHPS, CYP1B1, CYP2S1 FFAR1 1004/4885SLC9A1 4551/4885HTR2A 302/4885
US-20110137056-A1 Chemical Process For Preparation Of Intermediates DHPS, CYP3A5, CYP3A43 FFAR1 935/4885SLC9A1 4532/4885HTR2A 3056/4885
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1I, CACNA1G, CACNA1H FFAR1 1708/4885SLC9A1 354/4885HTR2A 1193/4885
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS TRPV3, CACNA1G, TRPV2 FFAR1 1881/4885SLC9A1 440/4885HTR2A 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.